INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH (EIN 460475333) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2002

Legal Domicile

Principal Officer

JAMES R BERENSON MD

Phone

3106231210

Tax Period

2024-01-01 to 2024-12-31

INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH, founded in 2002, is a community nonprofit in the Diseases & Disorders sector that reported $2.1M in total revenue in fiscal year 2024. Revenue surged 86% from the prior year, signaling strong growth momentum. The organization ran a surplus of $723K, a strong 34% operating margin.

Mission

FORM 990 PART I LINE 1 THE INSTITUTE FOR MYELOMA AND BONE CANCER RESERACH IS ESTABLISHED FOR THE FOLLOWING PURPOSES: (I) TO PROMOTE RESEARCH INTO THE CAUSES OF MYELOMA, BONE CANCER, AND RELATED DISORDERS, (II)TO SUPPORT THE DEVELOPMENT OF THERAPIES DESIGNED TO TREAT AND CONTROL MYELOMA, BONE CANCER, AND RELATED DISORDERS, AND (III) TO ADVANCE EFFORTS DIRECTED AT PREVENTING THE DEVELOPMENT OF MYELOMA, BONE CANCER, AND RELATED DISORDERS, INCLUDING THE TREATMENT OF PERSONS HAVING SUCH DISEASES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $1,547,145

Program Service Revenue $121,761

Investment Income $1

Other Revenue $468,291

TOTAL REVENUE $2,137,198

Expense Breakdown

Grants Paid $0

Salaries & Benefits $360,511

Fundraising Expenses $80,096

Program Expenses $328,124

Other Expenses $1,054,058

TOTAL EXPENSES $1,414,569

Year-over-Year Comparison

	2024	2023	Change
Revenue	$2,137,198	$1,146,011	+0.9%
Expenses	$1,414,569	$1,293,096	+0.1%
Net Income	$722,629	$-147,085	-5.9%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JAMES R BERENSON MD	PRESIDENT AN	10.00	Officer Director	$0	$0	$0
GEO HARTLEY ESQ	VICE PRESIDE	1.50	Officer Director	$0	$0	$0
SHAHROOZ ESHAGHIAN MD	SECRETARY	0.75	Director	$0	$0	$0
CYNDIE DUNLAP	DIRECTOR	0.75	Director	$0	$0	$0
ROGER FISCHER	DIRECTOR	0.75	Director	$0	$0	$0
RICHARD GARDINER MD	DIRECTOR	0.75	Director	$0	$0	$0
RICHARD KALE ESQ	DIRECTOR	0.75	Director	$0	$0	$0
BLAKE MORRISON PHARMD	DIRECTOR	1.50	Director	$0	$0	$0
KELLEY NICHOLS	DIRECTOR	1.50	Officer Director	$0	$0	$0
MICHAEL SCHIFF ESQ	DIRECTOR	0.75	Director	$0	$0	$0
LARRY STEIN ESQ	DIRECTOR	0.75	Director	$0	$0	$0
MERRYL WERBER	DIRECTOR	0.75	Director	$0	$0	$0
JESSICA YATACO	TREASURER	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$2,137,198	$1,414,569	$1,494,310	$722,629
2023	$1,146,011	$1,293,096	$844,637	$-147,085
2022	$2,303,328	$1,450,344	$660,470	$852,984
2021	$1,373,547	$2,654,225	$278,054	$-1,280,678
2020	$2,661,444	$1,404,338	$706,051	$1,257,106
2019	$584,714	$3,370,596	$133,838	$-2,785,882
2018	$1,023,481	$1,654,660	$412,082	$-631,179

INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH